Brainsway Ltd is a leading company in the field of neuroscience and mental health. Its business model revolves around the development and commercialization of advanced non-invasive medical devices for treating various brain disorders. Brainsway manufactures and markets Deep Transcranial Magnetic Stimulation (dTMS) systems, which are scientifically proven to be effective in treating major depressive disorder and obsessive-compulsive disorder. By leveraging cutting-edge technology and clinical expertise, Brainsway aims to provide patients with safe, non-pharmacological treatment options that can significantly improve their quality of life.

Brainsway Ltd is primarily active in the medical technology and healthcare industry.

The main competitors of Brainsway Ltd in the market are Magstim, Nexstim, and Neuronetics.

Brainsway Ltd. is a leading medical technology company specializing in the field of neuroscience. Established in 2003, Brainsway has been at the forefront of developing and commercializing breakthrough therapies for various brain disorders. The company is known for its innovative Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which provides non-invasive and effective treatment options for psychiatric and neurological conditions, such as major depressive disorder and obsessive-compulsive disorder. Brainsway has a strong commitment to research and development, constantly striving to improve the lives of patients worldwide. With its proven track record, Brainsway Ltd. continues to be a prominent player in the neurostimulation market, offering hope and transformative solutions to those in need.

Brainsway Ltd has achieved significant milestones since its inception. The company has made notable advancements in the field of non-invasive brain stimulation technology. Some of its key achievements include the development and commercialization of Deep Transcranial Magnetic Stimulation (dTMS) systems, earning FDA clearance for various indications such as major depressive disorder and obsessive-compulsive disorder. Brainsway Ltd has also expanded its global presence by establishing partnerships with renowned medical institutions and distributors worldwide. These milestones demonstrate Brainsway Ltd's commitment to revolutionizing the treatment of psychiatric and neurological disorders through innovative and effective technologies.

Brainsway Ltd, a global leader in non-invasive brain stimulation technologies, is primarily present in multiple countries and regions across the world. With its headquarters in Israel, Brainsway Ltd has established a strong presence in North America, including the United States and Canada. Additionally, the company has expanded its operations in Europe, with a significant presence in countries such as Germany, France, Italy, and the United Kingdom. Brainsway Ltd's innovative therapies and advanced technology have garnered recognition and adoption in numerous healthcare facilities and research centers worldwide.

Brainsway Ltd represents a strong commitment to advancing neurology and psychiatry through innovative technologies. The company is renowned for its deep transcranial magnetic stimulation (dTMS) system, offering effective and non-invasive treatment options for various brain disorders. Brainsway focuses on enhancing patients' quality of life by delivering cutting-edge solutions for depression, OCD, and other neuropsychiatric conditions. The company's corporate philosophy revolves around a patient-centric approach, striving to provide accessible and safe treatments worldwide. Brainsway's commitment to research and development, along with its collaborative partnerships with leading medical institutions, ensures ongoing advancements in neurological and psychiatric care.

Brainsway Ltd is a leading company in the field of neuromodulatory technology specializing in non-invasive therapy options for neuropsychiatric disorders. The company utilizes its proprietary Deep TMS (Transcranial Magnetic Stimulation) platform to offer innovative therapy options for depression, obsessive-compulsive disorder, schizophrenia, ADHD, and other psychiatric disorders. The business model of Brainsway includes several business areas, including research and development, production, distribution, and clinical application. In the research and development area, the company works on developing and improving innovative neuromodulatory therapy options, collaborating closely with renowned academic institutions and clinical researchers worldwide. The production of Brainsway encompasses a wide range of neuromodulatory therapy devices and accessories used in clinical facilities worldwide. The company's offerings include therapy options for the treatment of depression, obsessive-compulsive disorder, schizophrenia, and ADHD. Brainsway provides various therapy devices specifically tailored to each indication, as well as accessories such as specialized electrodes to ensure the most effective treatment. In the distribution area, Brainsway relies on partnerships with medical device companies and clinics worldwide. The focus is on making the therapy options accessible to as many patients as possible and enabling medical professionals to have high flexibility and adaptability in the application of the therapy devices. Another core area of Brainsway's business model is the clinical application of its therapy options. The company collaborates with renowned institutions worldwide, offering its therapy devices and accessories for patient treatment. This collaboration involves working closely with physicians and clinics to ensure dosage and application regulation and maximize therapy effectiveness. Overall, Brainsway's business model is focused on the development and provision of innovative neuromodulatory therapy options for neuropsychiatric disorders. The company collaborates closely with researchers, medical professionals, and clinical facilities, offering a wide range of therapy devices and accessories for the treatment of various indications. Through close collaboration with medical device companies worldwide and a focus on each individual patient and practice, Brainsway aims to provide an effective and non-invasive treatment option for as many patients worldwide as possible.

Den forventede omsætning for Brainsway er 209,54 mio. USD. Denne værdi er baseret på aktuelle regnskabstal og afspejler virksomhedens forretningsmæssige udvikling.

Den forventede indtjening for Brainsway er 24,47 mio. USD. Nettoresultatet viser virksomhedens rentabilitet efter fradrag af alle omkostninger.

Kurs/indkomst-forholdet (P/E) for Brainsway er i øjeblikket 1.844,26. P/E-forholdet sammenligner den aktuelle aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Brainsway-aktien.

Pris/salg-forholdet (P/S) for Brainsway er i øjeblikket 215,34. P/S-forholdet sammenligner markedsværdien med den årlige omsætning og tjener som en værdiansættelsesindikator for Brainsway-aktien.

AlleAktien Kvalitetsscore for Brainsway er 4/10.

ISIN-koden for Brainsway er IL0011007189. ISIN (International Securities Identification Number) er en globalt unik identifikator til værdipapirer.

WKN-koden for Brainsway er A0NDVW. WKN (Wertpapierkennnummer) er et sekscifret tysk identifikationsnummer for værdipapirer.

Tickeren for Brainsway er BWAY.TA. Under dette børssymbol handles Brainsway-aktien på børsen.

Brainsway betalte udbytte hvert år i løbet af de sidste 0 år.

Brainsway bliver tildelt sektoren 'Sundhed'.

Udbytterne fra Brainsway udbetales i USD.